Abstract
Salivary epithelial cells from patients with primary Sjögren's syndrome (SS) undergo Fas-mediated apoptosis. Bcl-2 and Bcl-xL are apoptosis suppressing oncogenes. Very little is known about the role of these oncogene molecules in salivary epithelial cells. To investigate the possible prevention of salivary glandular destruction in SS by Bcl-2 and Bcl-xL, stable transfectants expressing these molecules were made from HSY cells, a human salivary epithelial cell line. HSY cells were transfected with an expression vector for human Bcl-2 or Bcl-xL. Stable transfectants were selected and apoptosis was induced by anti-Fas antibody. Apoptosis was quantified by propidium iodide staining followed by flow cytometry. Caspase activity was detected by immunohistochemical analysis and enzyme cleavage of DEVD-AMC, a fluorescent substrate. Response to carbachol, a muscarinic receptor agonist, and EGF was measured by Ca2+ mobilization and influx. Fas-mediated apoptosis was significantly inhibited in Bcl-2 and Bcl-xL transfectants compared to wild-type and control transfectants (empty vector). Surprisingly, caspase activity was not inhibited in Bcl-2 and Bcl-xL transfectants. Activation of the Fas pathway in the Bcl-2 and Bcl-xL transfectants by antibody also inhibited carbachol and EGF responsiveness (i.e., Ca2+ mobilization and/or influx) by 50–60%. This Fas-mediated inhibition of cell activation was partially or completely restored by specific peptide interference of caspase enzyme activity. The prevention of Fas-mediated apoptosis by the overexpression of Bcl-2 and Bcl-xL in salivary gland epithelial cells results in injured cells expressing caspase activity and unable to respond normally to receptor agonists. Such damaged cells may exist in SS patients and could explain the severe dryness out of proportion to the actual number of apoptotic cells seen on salivary gland biopsy. Cell Death and Differentiation (2000) 7, 1119–1126
Similar content being viewed by others
Introduction
CD95 (i.e., Fas or APO-1) is a cell surface receptor expressed in many different types of cells and tissues.1,2 When crosslinked by antibody or its physiological ligand (FasL) Fas sends an apoptotic signal to the cell.3 This signal includes the activation of a cascade of cysteine proteases called caspases4,5,6,7 and a rise in intracellular ceramide.5,8,9 Fas-mediated apoptosis is inhibited by the protooncogene bcl-210 in a cell type-dependent fashion.7 Fas-mediated apoptosis has been implicated in the pathogenesis of numerous diseases.11,12,13,14,15 Several organ-specific autoimmune diseases including Sjögren's syndrome (SS), diabetes mellitus, and thyroiditis, demonstrate coexpression of Fas/FasL suggesting that target cell death is initiated by Fas-mediated apoptosis.16,17,18,19
The bcl-2 family of protooncogenes plays an important role in regulating apoptosis.20 This family consists of both antagonists (e.g., bcl-2, bcl-xL) and agonists (e.g. bax) that cross-talk with one another through dimerization.21 For example, the family member bid heterodimerizes with both bcl-2 and bax. When cleaved by caspase 8, bid counters the cytoprotective effect of bcl-2 and promote the proapoptotic effect of bax.22 Any changes in this family of proteins, can alter the cell's sensitivity to an apoptotic signal.
The autoantigens that incite autoimmune disease are becoming better known. Recent evidence from several laboratories suggests that many of these antigens arise in cells undergoing apoptosis.23,24,25,26 These apoptotic autoantigens are thought to induce several antinuclear and antinucleoprotein antibodies seen in SLE and SS patients. We reported that SS salivary gland epithelial cells die apoptotically.16 The same is true in NOD mice (a model for SS), but surprisingly also in NOD.scid mice which lack a mature immune system.27 This unexpected result suggested a lymphocyte-independent early stage in SS patients in which the epithelial apoptotic lesion precedes and calls forth the lymphocytic autoimmune process.
To pursue this hypothesis, we studied a human salivary gland epithelial cell line (HSY) growing in tissue culture. We induced Fas-mediated apoptosis in these HSY cells and aborted cell death by stable transfection with bcl-2 or bcl-xL. These transfected cells still manifest caspase activation and have Fas-induced defects in intracellular [Ca2+]i signaling in response to carbachol and EGF. To our knowledge, this is the first report showing that the functional abnormalities associated with the Fas pathway can be segregated from apoptosis. These poorly functional cells may be a model for what occurs pathologically in SS patients where the severity of dryness is probably not solely a result of glandular destruction.
Results
Bcl-2 and Bcl-xL protect HSY cells from fas-mediated apoptosis
HSY cells were stably transfected for bcl-2 and bcl-xL expression. Transfectants only overexpressed their respective molecule as assessed by Western blot analysis (Figure 1). Furthermore, transfectants were responsive to carbachol, a muscarinic receptor agonist, and EGF (Figure 1). Sensitivity to Fas-mediated apoptosis was assessed by adding anti-Fas antibody, CH11, to cell cultures (Figure 2). After 48 h the classical DNA laddering pattern typical of apoptotic cells was seen in the empty vector transfectant but not in the bcl-2 and bcl-xL transfectant (data not shown). Further confirmation of the antiapoptotic action of bcl-2 and bcl-xL in HSY cells was obtained by quantifying apoptosis by propidium iodide staining (Figure 2A). More than 80% of the empty vector transfectants were apoptotic, whereas the bcl-2 and bcl-xL transfectants were resistant to Fas-mediated apoptosis (11 and 8% apoptotic, respectively, P<0.05). Furthermore, Fas-mediated apoptosis in HSY was caspase-dependent as DEVD inhibited cell death (Figure 2A). C2-ceramide, a lipid second messenger for Fas, was added to cultures. As with CH11, bcl-2 and bcl-xL transfectants were resistant to ceramide-induced apoptosis compared to the control transfectant (70 vs 10 and 6% apoptotic, respectively; P<0.05). Upregulation of bcl-2 or bcl-xL totally protected HSY cells from apoptosis and did not merely delay apoptosis. The number of apoptotic cells did not increase after 4 days in culture with CH11.
Forward light scatter (Figure 2B) showed that anti-Fas antibody did not alter cell size in the bcl-2 and bcl-xL transfectants. By contrast, cell size was reduced in the wild-type and the control transfectant after 48 h of exposure to CH-11.
Fas-mediated signaling abnormalities in Bcl-2 and Bcl-xL transfectants
Transfectants were treated with CH11 (anti-Fas antibody) and assessed for cell function by measuring intracellular free [Ca2+]i in response to carbachol and EGF (Figure 3). After 24 h, a time when nuclear condensation, DNA fragmentation, and cell shrinkage was not observed, control transfectants showed decreased responses to carbachol and EGF compared to cultures with no anti-Fas antibody. Although the bcl-xL transfectant was resistant to Fas-mediated apoptosis it was nevertheless defective in response to carbachol and EGF following exposure to CH11. The abnormality in Ca2+ release from intracellular stores was not observed in the bcl-2 transfectants. However, C2-ceramide significantly inhibited carbachol responses in all three transfectants (Figure 4).
Extracellular Ca2+ influx is another measurement of signal transduction. Anti-Fas antibody decreased in Ca2+ influx by 30–50% in all three transfectants (Figure 5). Fas-induced inhibition of Ca2+ influx was not affected by the overexpression of either bcl-2 and bcl-xL.
Caspase 3 is activated in the Fas-stimulated Bcl-2 and Bcl-xL transfectants
Fas stimulation leads to the activation of a cascade of cysteine proteases called caspases.28 The caspase inhibitor DEVD or VAD was added to cultures and the transfectants assessed for intracellular [Ca2+]i response to carbachol and EGF (Figure 3). The presence of DEVD partially restored intracellular signaling in the control transfectant and wild-type HSY. Whereas, DEVD countered the inhibitory effect of CH-11 and restored responsiveness to carbachol and EGF in the bcl-xL transfectants. The presence of VAD was much more effective in restoring carbachol and EGF responsiveness in all of the cell lines. Indeed, the presence of DEVD and VAD heightened the carbachol and EGF response.
DEVD and VAD were used to counter the inhibitory effect of ceramide (Figure 4). The presence of these two caspase inhibitors had no effect. This suggest that Fas-mediated inhibition of cell activation was not initiated by the generation of ceramide.
Immunohistochemical and enzymatic analysis was performed (Figures 6 and 7, respectively) to further demonstrate caspase activation in the absence of apoptosis. After 24 h with anti-Fas antibody, all three transfectants stained positive for activated caspase 3. Furthermore, caspase activity was quantified in cell lysates from transfectants (Figure 7). Transfectants were treated with anti-Fas antibody (CH11) or C2-ceramide, and lysates were assessed for cleavage of DEVD-AMC by fluorometry. After 24 h, CH11 and C2-ceramide induced 8–12 times as much caspase activity in the control transfectant compared to untreated cells. Similar levels of caspase activation was seen in the bcl-2 and bcl-xL transfectants.
Discussion
These experiments were undertaken to study the role of salivary gland epithelial cell apoptosis and its inhibition in the pathogenesis of SS. Based on our previous studies in SS patients we show that anti-Fas antibody induces apoptosis in a human salivary gland cell line (HSY). We found that enforced expression of the suppressor protooncogene bcl-2 and bcl-xL largely prevented HSY epithelial cells from undergoing Fas-mediated apoptosis, although caspase enzymes were activated. The rescued cells showed decreased [Ca2+]i release and/or Ca2+ influx in response to carbachol and EGF following the activation of the Fas pathway. Signal transduction suppression by Fas has been reported in T lymphocytes prior to the onset of apoptosis (i.e. decreased nuclear content).29 Thus bcl-2 and bcl-xL can abort Fas-mediated apoptosis but leave these damaged cells functionally abnormal. This system may provide an in vitro model for SS, where the severe dryness cannot be totally explained by actual number of apoptotic acinar cells found in the gland.16,30 It is interesting to note that nonapoptotic mechanisms may also explain the salivary dysfunction in irradiated rat salivary glands.31
Bcl-2 and bcl-xL represent a family of homologous proteins that regulate several apoptotic pathways.20 These proteins act at the site of the mitochondria to maintain membrane potential. The partial restoration of [Ca2+]i cell signaling in the bcl-2 and bcl-xL transfectants can be attributed to the control the mitochondria exert over endoplasmic reticulum [Ca2+]i.32 At the mitochondrial level bcl-2 and bcl-xL can regulate the activation of caspases.33 The regulation of caspase activity by bcl-2 or bcl-xL is cell type-dependent.7 In the B cell line, SKW6, overexpression of bcl-2 or bcl-xL inhibited Fas-mediated cell death but not caspase 3 activation, similar to what we find with HSY cells where caspase 3-like activation occurs in the absence of apoptosis. The lymphoblastoid T cell line JURKAT transfected with bcl-xL was resistant to Fas-mediated apoptosis.34 Nevertheless, PARP was cleaved in these cells. Moreover, caspase 3 or 8 activation in the absence of apoptosis has been observed in activated cells.35,36,37
Increase in [Ca2+]i is related to fluid secretion from salivary glands epithelial cells.38 In salivary acinar cells, stimulation of the muscarinic receptor results in activation of phospholipase C and the subsequent hydrolysis of phosphatidylinositol 4,5-bisphosphate to diacylglycerol and inositol 1,4,5-triphosphate. The former is an endogenous activator of protein kinase C which results in a rapid release of Ca2+ from intracellular stores.39 EGF receptor is a transmembrane protein tyrosine kinase. Binding of EGF lead to receptor dimerization, autophosphorylation, and recruitment of kinase substrates. Subsequent events include Ras (GTP-binding protein) phosphorylation and activation of the Ras/Raf/MAP kinase pathway.40 Like the muscarinic receptor, the EGF receptor can activate the phosphatidylinositol pathway resulting in the activation of protein kinase C and a rise in [Ca2+]i and Ca2+ influx.41 Fas signaling may affect both common and distinct pathways in these two receptor systems.
The Fas-mediated signaling abnormalities in HSY transfectants were partly or completely restored by caspase inhibitors, suggesting the involvement of proteolysis in this abnormality. Certain transcription factors which arise during cell activation are susceptible to proteolysis by caspases.42,43 Apoptotic enterocytes downregulate molecules involved in Ras signaling.44 These include the disappearance of the EGF receptor and the guanine nucleotide exchangers, Sos-1 and Sos-2. In that work the addition of a caspase inhibitor prevented the disappearance of these signal transduction molecules. Similar mechanisms may be operating in HSY cells.
There may also be caspase-independent mechanisms present in HSY cells, even in the bcl-2 and bcl-xL transfectants. For example, ceramide generation may play a role. This lipid second messager for Fas can disrupt electron transport and ATP synthesis without perturbing mitochondrial membrane potential.45,46 Fas stimulation can also lead to c-Jun kinase activity, perhaps through the Daxx adapter molecule,47 which may send a negative regulatory signal that interferes with carbachol and EGF signaling. Loss of glucose transport is another early event in Fas-mediated apoptosis that can disrupt normal signal transduction.48
The current study suggests that Fas can also disrupt normal cell signaling without inducing apoptosis. The disassociation between apoptosis and abnormal cell signaling provides a new model for disease pathogenesis. Based on our work in NOD mice and patients, Fas/FasL interaction occurs abnormally in the salivary gland.16,27 This model in which inappropriate expression of Fas or FasL of target cells may also apply to other organ-specific autoimmune diseases such as Hashimoto's thyroiditis13 and insulin-dependent diabetes mellitus.49
Materials and Methods
Cell preparation
HSY is an adenocarcinoma cell line derived from an acinar-intercalated duct region of a human parotid gland.50 The HSY cell line was developed by Dr. Patton (NIH) and kindly provided by Dr. JT Turner (NIDCR, NIH). Cells were cultured in Dulbecco's Modified Eagle's medium (Gibco BRL, Gaithersburg, MD, USA), 10% FCS (Gibco BRL), 10% L-glutamine (Gibco BRL) and penicillin-streptomycin (Gibco BRL), 6% CO2. Transfected cells were cultured in medium as described but containing 500 μg/ml Geneticin (Gibco BRL).
Antibodies and reagents
Mouse monoclonal anti-Fas antibody, CH11, was purchased from Upstate Biotechnology Inc. (Lake Placid, NY, USA). Mouse monoclonal antibodies to bax, bcl-2 and bcl-xL were purchased from Trevigen Inc (Gaithersburg, MD, USA). Alkaline phosphatase-conjugated streptavidin and 7-amino-4-methylcoumarin (AMC) were from Sigma Chemical Co. (St Louis, MO, USA). Ac-DEVD-AMC, a caspase-3 (cpp 32) fluorogenic substrate, rabbit antibody to activated caspase 3, and APO-BRDUTM kit were purchased from PharMingen (San Diego, CA, USA). LipofecTAMINETM reagent was purchased from Gibco BRL Life Technologies, Inc (Gaithersburg, MD, USA). Z-Asp-Glu-Val-Asp-CH2F (DEVD) and Z-Val-Ala-Asp-CH2F (VAD) was from Enzyme System Products Inc (Dublin, CA, USA). C2-ceramide and (OH)2-C2-ceramide, a biologically inert form of C2-ceramide, was purchased from CalBiochem (La Jolla, CA, USA).
Stable cell transfection
Plasmids pSFFV-neo (the empty vector), pSFFV.neo-Bcl-2 and pSFFV.neo-Bcl-xL were kind gifts from Dr. C Thompson10 (University of Chicago Medical Center). HSY cells were grown to 80% confluency and rinsed with serum-free medium followed by the addition of a mixture of plasmid (1 μg) and lipofecTAMINETM (10 μl) in serum-free medium. After 18 h at 37°C, FCS was added to a final concentration of 10% for 6 h. Transfectants were selected for drug resistance with Geneticin (500 μg/ml). Resistant colonies were transferred to tissue culture plates. Western blot analysis was used to assess overexpression of bcl-2 or bcl-xL of isolated clones.
Propidium iodide staining
Cells (1×106) were resuspended in hypotonic buffer containing propidium iodide (50 μg/ml, 0.1% sodium citrate, 0.1% Triton X-100) overnight at 4°C in the dark as described by Nicoletti et al.51 DNA content was quantified by flow cytometry. Cells in the hypodiploid region were defined as apoptotic.
DNA fragmentation
DNA was extracted from ten million cells using the Trevigen DNA laddering kit (Gaithersburg, MD, USA). DNA was separated by gel electrophoresis in 3% agarose and visualized by ethidium bromide staining.
Immunohistochemical assessment
Transfectants were fixed with 4% paraformaldehyde and washed in Tris buffered saline (pH 7.6). Rabbit antibody specific for the activated form of caspase 3 (1 : 40 v/v) as added to the fixed cells for 30 min at room temperature. A peroxidase immunoconjugate was subsequently added (1 : 100 v/v) followed by biotinyl tyramide (1 : 50 v/v) and alkaline phosphatase-conjugated streptavidin. Color development was achieved with Vector Red (Vector Laboratories, Burlingame, CA, USA) and counterstained with hematoxylin.
Detection of caspase activation
Cells were incubated with anti-Fas antibody or C2-ceramide for 24 h and resuspended in lysis buffer (10 mM Tris, pH 7.5, 130 mM NaCl, 1% Triton X-100) on ice for 5 min. One hundred μg of cell lysates was incubated with 20 μM of Ac-DEVD-AMC in 1 ml of 20 mM HEPES (pH 7.5, 10% glycerol, 2 mM DTT) for 2 h at 37°C. A spectrofluorometer was used to measure liberated AMC from Ac-DEVD-AMC using an excitation wavelength of 380 nm and an emission wavelength of 445 nm. A standard curve using AMC was used to quantify caspase activity.
Intracellular [Ca2+]i and Ca2+ influx
[Ca2+]i and Ca2+ influx was quantified by spectrofluorometry using Fura-2AM (Molecular Probes, Eugene, OR, USA) as the fluorescent dye. Cells were loaded with 2 μM of Fura-2Am for 45 min at 30°C.52 Fluorescent wavelength measurements were set at 340 and 380 nm excitation, and 510 nm emission. Readings were done on a PTI Systems Delta Scan spectrofluorometer (Photo Technology International Inc., South Brunswick, NJ, USA). Cytosolic free [Ca2+]i was calculated according to Vandenberghe et al.53 After a basal level of free [Ca2+]i was established, cells were stimulated by the addition of carbachol (10 μM final concentration) or EGF (50 ng/ml final concentration). Readings were done in either media containing Ca2+ (100 mM) or were Ca2+-free. The latter was required to measure Ca2+ influx.
Statistical analysis
Nonparametric Student's t-test was used. P<0.05 was considered statistically significant.
Abbreviations
- SS:
-
Sjögren's syndrome
- FasL:
-
Fas ligand
- EGF:
-
epidermal growth factor
References
Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima SI, Sameshima M, Hase A, Seto Y and Nagata S . 1991 The polypeptide encoded by the cDNA for human cell surface antigen fas can mediate apoptosis. Cell 66: 233–243
Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, Li-Weber M, Richards S, Dheim J, Trauth BC, Ponsting H and Krammer PH . 1992 Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. J. Biol. Chem. 267: 10709–10715
Nagata S and Golstein P . 1995 The Fas death factor. Science 267: 1449–1456
Enari M, Hug H and Nagata S . 1995 Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 375: 78–81
Cifone MG, Roncaioli P, De Maria R, Camarda G, Santoni A, Ruberti G and Testi R . 1995 Multiple pathways originate at the Fas/APO-1 (CD95) receptor: sequential involvement of phosphatidylcholine-specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signal. EMBO J. 14: 5859–5868
Los M, Van de Craen M, Penning LC, Schenk H, Westendorp M, Baeuerle PA, Dröge W, Krammer PH, Fiers W and Schulze-Osthoff K . 1995 Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature 375: 81–83
Scaffidi CS, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin K-M, Krammer PH and Peter ME . 1998 Two CD995 (APO-1/Fas) signaling pathways. EMBO J. 17: 1675–1687
Gill BM, Nishikata H, Chan G, Delovitch TL and Ochi A . 1994 Fas antigen and sphingomyelin-ceramide turnover-mediated signaling: role in life and death of T lymphocytes. Immunol. Rev. 142: 113–145
Cifone MG, De Maria R, Roncaioli P, Rippo MR, Azuma M, Lanier LL, Santoni A and Testi R . 1994 Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. J. Exp. Med. 180: 1547–1552
Boise LH, Gonzalez-Gracia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nuñez G and Thompson CB . 1993 bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597–608
Wilson SE, Li Q, Weng J, Barry-Lane PA, Jester JV, Liang Q and Wordinger RJ . 1996 The Fas-Fas ligand system and other modulators of apoptosis in the cornea. Invest. Ophthalmol. Vis. Sci. 37: 1582–1592
Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, Krammer PH and Runkel L . 1995 Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 182: 1223–1230
Giordano C, Stassi G, D Maria R, Todaro M, Richiusa P, Papoff G, Ruberti G, Bagnasco M, Testi R and Galluzzo A . 1997 Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 275: 960–963
Kondo T, Suda T, Fukuyama H, Adachi M and Nagata S . 1997 Essential roles of the Fas ligand in the development of hepatitis. Nat. Med. 9: 409–413
Schelling JR, Nkemere N, Kopp J and Cleveland RP . 1998 Fas-dependent fratricidal apoptosis is a mechanism of tubular epithelial cell deletion in chronic renal failure. Lab. Invest. 78: 813–824
Kong L, Ogawa N, Nakabayashi T, Liu GT, D'Souza E, McGuff HS, Guerrero D, Talal N and Dang H . 1997 Fas and Fas ligand expression in salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum. 39: 87–97
Nakajima T, Aono H, Hasunuma T, Yamamoto K, Shirai T, Hirohata K and Nishioka K . 1995 Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum. 38: 485–491
Dowling P, Shang G, Raval S, Menonna J, Cook S and Husar W . 1996 Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J. Exp. Med. 184: 1513–1518
De Maria R and Testi R . 1998 Fas-FasL interactions: a common pathogenetic mechanism in organ-specific autoimmunity. Immunol. Today 19: 121–125
Green DR and Reed JC . 1998 Mitochondria and apoptosis. Science 281: 1309–1312
Oltvai ZN and Korsmeyer SJ . 1994 Checkpoints of dueling dimers foil death wishes. Cell 79: 189–192
Wang K, Yin XM, Chao DT, Milliman CL and Korsmeyer SJ . 1996 BID: a novel BH3 domain-only death agonist. Genes Dev. 10: 2859–2869
Casciola-Rosen LA, Anhalt G and Rosen A . 1994 Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J. Exp. Med. 179: 1317–1330
Tan EM . 1994 Autoimmunity and apoptosis. J. Exp. Med. 179: 1083–1086
Casciola-Rosen L, Rosen A, Petri M and Schlissel M . 1996 Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythemeatosus. Proc. Natl. Acad. Sci. USA 93: 1624–1629
Pittoni V and Isenberg D . 1998 Apoptosis and antiphospholipid antibodies. Semin. Arthritis Rheum. 28: 163–178
Kong L, Robinson CP, Peck AB, Vela-Roch N, Sakata KM, Dang H, Talal N and Humphreys-Beher MG . 1998 Inappropriate apoptosis of salivary and lacrimal gland epithelium of immunodeficient NOD-scid mice. Clin. Exp. Rheumatol. 16: 675–681
Ji L, Ito M, Zhang G, Hirabayashhi Y, Inokuchi J and Yamagata T . 1998 Effects of endoglycoceramidase of D-threo-1-phenyl-2-decanoylamino-3 morpholino-1-propanol on glucose uptake, glycolysis, and mitochondrial respiration in HL60 cells. Arch. Biochem. Biophys. 359: 107–114
Yang X, Khosravi-Far R, Chang HY and Baltimore D . 1997 Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 89: 1067–1076
Berridge MV, Tan AS, McCoy KD, Kansara M and Rudert F . 1996 CD95 (Fas/Apo-1)-induced apoptosis results in loss of glucose transporter function. J. Immunol. 156: 4092–4099
Sainio-Pollanen S, Erkkila S, Alanko S, Hanninen A, Pollanen P and Simell O . 1998 The role of Fas ligand in the development of insulitis in nonobese diabetic mice. Pancreas 16: 154–159
Martin SJ and Green DR . 1995 Protease activation during apoptosis: death by a thousand cuts. Cell 82: 349–352
Kovacs B and Tsokos GC . 1995 Cross-linking of the Fas/Apo-1 antigen suppresses the CD3-mediated signal transduction events in human T lymphocytes. J. Immunol. 155: 5543–5549
Kong L, Ogawa N, McGuff HS, Nakabayashi T, Sakata K-M, Masago R, Vela-Roch N, Talal N and Dang H . 1998 Bcl-2 family expression in salivary glands from patients with primary Sjögren's syndrome: involvement of bax in salivary gland destruction. Clin. Immunol. Immunopathol. 88: 133–141
Paardekooper GM, Cammelli S, Zeilstra LJ, Coppes RP and Konings AW . 1998 Radiation-induced apoptosis in relation to acute impairment of rat salivary gland function. Int. J. Radiat. Biol. 73: 641–648
Hoth M, Fanger CM and Lewis RS . 1997 Mitochondrial regulation of store operated calcium signaling in T lymphocytes. J. Cell. Biol. 137: 633–648
Susin SA, Zamzami N, Castedo M, Hirsch T, Marchetti P, Macho A, Daugas E, Geusken M and Kroemer G . 1996 Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J. Exp. Med. 184: 1331–1341
Boise LH and Thompson CB . 1997 Bcl-x(L) can inhibit apoptosis in cells that have undergone Fas-induced protease activation. Proc. Natl. Acad. Sci. USA 94: 3759–3764
Miossec C, Dutilleul V, Fassey F and Diu-Hercend A . 1997 Evidence for CPP32 activation in the absence of apoptosis during T lymphocyte stimulation. J. Biol. Chem. 272: 13459–13462
Wilhelm S, Wagner H and Häcker G . 1998 Activation of caspase-3-like enzymes in non-apoptotic T cells. Eur. J. Immunol. 28: 891–900
Kennedy NJ, Kataoka T, Tschopp J and Budd RC . 1999 Caspase activation is required for T cell proliferation. J. Exp. Med. 190: 1891–1896
Puney Jr JW . 1986 Identification of cellular activation mechanism associated with salivary secretion. Annu. Rev. Physiol. 48: 75–88
Ambudkar IS, Hiramatsu Y, Lockwich T and Baum BJ . 1993 Activation and regulation of calcium entry in rat parotid gland acinar cells. Crit. Rev. Oral Biol. Med. 4: 421–425
Teitebaum I . 1990 The epidermal growth factor receptor is coupled to a phospholipase A2-specific pertussis toxin-inhibitable guanine nucleotide-binding regulatory protein in cultured rat inner medillary collecting tubule cells. J. Biol. Chem. 265: 4218–4222
Pai R and Tarnawski A . 1998 Signal transduction cascades triggered by EGF receptor activation: relevance to gastric injury repair and ulcer healing. Dig. Dis. Sci. 43: 14S–22S
King P and Goodburn S . 1998 STAT1 is inactivated by a caspase. J. Biol. Chem. 273: 8699–8794
Ravi R, Bedi A, Fuchs EJ and Bedi A . 1998 CD95 (Fas)-induced caspase-mediated proteolysis of NF-kappaB. Cancer Res. 58: 882–886
Scheving LA, Jin W-H, Chong K-M, Gardner W and Cope FO . 1998 Dying enterocytes downregulate signaling pathways converging on Ras: rescue by protease inhibition. Am. J. Physiol. 274: C1363–C1372
France-Lanord V, Brugg B, Michel PP, Agid Y and Ruberg M . 1997 Mitochondrial free radical signal in ceramide-dependent apoptosis: a putative mechanism for neuronal death in Parkinson's disease. J. Neurochem. 69: 1612–1621
Patton L, Pollack S and Wellner R . 1991 Responsiveness of a human parotid epithelial cell line (HSY) to autonomic stimulation: muscarinic control of K+ transport. In vitro Cell. Dev. Biol. 27A: 779–785
Nicoletti I, Migliorati G, Pagliacci MC, Grigani F and Riccardi C . 1991 A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods. 139: 271–279
Olsen JG, Salih MA, Harrison JL, Herrera I, Luther MF, Kalu DN, Lifschitz MD, Katz MS and Yeh C-K . 1997 Modulation by food restriction of intracellular calcium signaling in parotid acinar cells of aging Fischer 344 rats. J. Gerontol. 52A: B152–B158
Vandenberghe PA and Ceuppens JL . 1990 Flow cytometric measurement of cytoplasmic free calcium in human peripheral blood T lymphocytes with fluo-3, a new fluorescent calcium indicator. J. Immunol. Methods. 127: 197
Acknowledgements
The authors are grateful to Drs. Rudin and Lee for their advice and help in establishing stable transfectants; and Charles Thomas for flow cytometric analysis. Support for this work was provided by grants from the RGK Foundation (Austin, TX) and National Institute of Dental and Craniofacial Research (DE10863 and DE12203 to H Dang; DE90270 to GH Zhang; DE12188 to C-K Yeh).
Author information
Authors and Affiliations
Corresponding author
Additional information
Edited by JC Reed
Rights and permissions
About this article
Cite this article
Liu, XB., Masago, R., Kong, L. et al. G-protein signaling abnormalities mediated by CD95 in salivary epithelial cells. Cell Death Differ 7, 1119–1126 (2000). https://doi.org/10.1038/sj.cdd.4400745
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cdd.4400745
Keywords
This article is cited by
-
Cholinergic receptor pathways involved in apoptosis, cell proliferation and neuronal differentiation
Cell Communication and Signaling (2009)